Failure to Act on Pharmacist Recommendation for Antipsychotic Taper
Summary
The deficiency involves the facility’s failure to act on a pharmacist’s medication regimen review (MRR) recommendation for a resident receiving aripiprazole for depression. The resident was admitted with a diagnosis including depression and had a physician’s order for aripiprazole 5 mg daily. A pharmacist completed an MRR on 1/7/26, including an Abnormal Involuntary Movement Scale (AIMS) assessment that showed no involuntary movements and no new recommendations. On 2/2/26, the pharmacist’s subsequent MRR included a recommendation to consider tapering the resident off aripiprazole and introducing a different medication for depression if appropriate. The Medical Director documented agreement with this recommendation and wrote a note dated 2/24/26 indicating that the Nurse Practitioner would follow up regarding a taper or a psychiatry consult. Record review showed that despite the pharmacist’s recommendation and the Medical Director’s documented agreement, the resident continued to receive aripiprazole 5 mg daily with no evidence of dose taper attempts or a psychiatry referral. Medication administration records for February and March showed ongoing daily administration of aripiprazole per the original order, and the April record showed continued administration on the first two days of the month. The resident’s AIMS assessment on 2/24/26 again showed a score of zero, indicating no abnormal involuntary movements, but there was no provider documentation addressing the pharmacist’s recommendation, no documented clinical decision about whether to taper, and no initiation of psychiatric services. Interviews revealed confusion and breakdowns in responsibility for following up on the pharmacist’s recommendation. The Primary NP stated she was not responsible for antipsychotic taper follow-up and believed psychiatric issues were handled by the Psychiatric NP, and she reported she had never seen the 2/2/26 recommendation or been aware of a directive to follow up. The Psychiatric NP reported she did not know the resident and had never received a referral. The Medical Director recalled the recommendation and believed the NP would complete the follow-up but was unaware it had not occurred. The DON and ADON described a process in which pharmacy recommendations were emailed to the ADON, printed, and hand-delivered to providers, with the ADON stating she monitored recommendations and had re-delivered the 2/2/26 recommendation to the Primary NP after noticing no apparent action. Despite these processes, there was no documented provider response or action on the pharmacist’s recommendation for this resident’s aripiprazole therapy.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.